<DOC>
	<DOC>NCT02936804</DOC>
	<brief_summary>The present study is a single arm clinical trial aiming to improve the key technology in the diagnosis and treatment of early stage lung cancer. 60,000 high-risk subjects (age 45-70) are planned to recruit and assign to the Low Dose Computed Tomography (LDCT) screening arm (Baseline + 2 rounds of biennial repeated LDCT screening). Management of positive screening test will be carried out by a pre-specified protocol.</brief_summary>
	<brief_title>Precision Diagnosis and Therapy for Early Stage Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<criteria>• Eligible participants were those aged 4570 years, and with either of the following risk factors: 1. history of cigarette smoking ≥ 20 packyears, and, if former smokers, had quit within the previous 15 years; 2. malignant tumors history in immediate family members; 3. personal cancer history; 4. professional exposure to carcinogens; 5. long term exposure to secondhand smoke; 6. long term exposure to cooking oil fumes. 1. Had a CT scan of chest within last 12 months 2. History of any cancer within 5 years</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>early stage lung cancer</keyword>
	<keyword>LDCT screening</keyword>
	<keyword>lung resection</keyword>
	<keyword>electromagnetic navigation bronchoscopy</keyword>
	<keyword>peripheral biomarker</keyword>
</DOC>